Notable Labs, Ltd. NTBLQ
- Market cap
- $2.4M
- P/E
- 0.0×
Follow NTBLQ
Target Price Range
Analyst price targets
Free account| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | 96.60 | 136.50 | 21.00 | 32.55 | 31.50 | 57.75 | 3.54 | 1.82 |
Analyst estimates 2024–2026 Powerpack |
Low Price
|
||
| — | — | 265.30 | 316.75 | 306.25 | 66.50 | 72.10 | 110.95 | 77.00 | 11.20 |
High Price
|
|||
| — | — | 34 | 37 | 39 | 38 | 38 | 41 | 7 | 16 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 14 | 1 | 1 | 1 | 1 | 0 | 0 |
Revenue
|
|||
| — | — | 0.00% | 97.55% | 59.83% | 60.50% | 57.27% | 52.47% | 100.00% | 36.45% |
Gross Margin
|
|||
| — | — | (16) | (10) | (20) | (19) | (24) | (30) | (14) | (11) |
EBT
|
|||
| — | — | 0.00% | (73.12%) | (3,497.09%) | (3,451.25%) | (2,627.44%) | (3,895.83%) | (180,087.50%) | (3,633.55%) |
EBT Margin
|
|||
| — | — | (16) | (10) | (20) | (19) | (24) | (30) | (14) | (11) |
Net Income
|
|||
| — | — | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
Depreciation
|
|||
| — | — | 0.00 | 17.69 | 0.62 | 0.55 | 0.74 | 0.40 | 0.01 | 0.09 |
Revenue/Sh
|
|||
| — | — | (22.38) | (12.94) | (21.68) | (18.88) | (19.23) | (15.73) | (21.96) | (3.41) |
Earnings/Sh
|
|||
| — | — | (18.78) | (4.88) | (16.63) | (12.75) | (18.72) | (13.17) | (17.75) | (4.15) |
Cash Flow/Sh
|
|||
| — | — | (0.69) | (8.27) | (2.36) | (0.07) | (0.04) | (0.77) | 0.08 | (0.02) |
Capex/Sh
|
|||
| — | — | (19.47) | (13.15) | (18.99) | (12.83) | (18.76) | (13.94) | (17.66) | (4.17) |
Free CF/Sh
|
|||
| — | — | 59.37 | 71.34 | 56.31 | 35.10 | 24.76 | 26.66 | (56.35) | 4.58 |
Book Value/Sh
|
|||
| — | — | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 3 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 0.00 | 54.72 | 76.69 | 89.60 | 170.36 | 387.86 | 759.69 |
PS Ratio
|
|||
| — | — | — | 3.53 | 0.60 | 1.20 | 2.67 | 2.59 | 0.00 | 0.40 |
PB Ratio
|
|||
| — | — | — | 0.00 | (30.81) | 11.86 | 58.74 | 103.52 | 363.86 | (685.56) |
EV/Sales
|
|||
| — | — | — | (13.85) | 1.01 | (0.51) | (2.31) | (3.01) | (0.25) | 0.40 |
EV/FCF
|
|||
| — | — | (13) | (4) | (16) | (13) | (23) | (25) | (12) | (14) |
Op' Cash Flow
|
|||
| — | — | 0 | (6) | (2) | 0 | 0 | (1) | 0 | 0 |
Capex
|
|||
| — | — | (14) | (10) | (18) | (13) | (23) | (26) | (12) | (14) |
FCF
|
|||
| — | — | 42 | 51 | 47 | 29 | 25 | 45 | 1 | 13 |
Working Cap'
|
|||
| — | — | — | — | 0 | 0 | 2 | 2 | 1 | 0 |
Total Debt
|
|||
| — | — | (45) | (55) | (50) | (36) | (28) | (51) | (2) | (12) |
Net Debt
|
|||
| — | — | 42 | 56 | 53 | 36 | 31 | 51 | (37) | 15 |
Sh' Equity
|
|||
| — | — | (36.99%) | (17.95%) | (32.38%) | (35.37%) | (53.41%) | (56.26%) | (41.06%) | (89.92%) |
ROA
|
|||
| — | — | 0.00% | (568.69%) | (433.15%) | 0.00% | (611.83%) | 0.00% | 0.00% | (257.90%) |
ROIC
|
|||
| — | — | (41.35%) | (20.63%) | (37.54%) | (43.53%) | (72.38%) | (73.43%) | (211.68%) | 103.08% |
ROE
|
|||
Notable Labs, Ltd. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PPBT Purple Biotech Ltd. Sponsored ADR | $2.4M | 0.0× | Compare |
| CDT CDT Equity Inc. | $2.4M | 0.0× | Compare |
| MTNB Matinas Biopharma Holdings, Inc. | $2.4M | 0.0× | Compare |
| BPTSY Biophytis SA Sponsored ADR | $2.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| WINT Windtree Therapeutics, Inc. | $2.4M | 0.0× | Compare |
| BIORQ Biora Therapeutics, Inc. | $2.5M | 0.0× | Compare |
| OGEN Oragenics, Inc. | $2.3M | 0.4× | Compare |
| EIGRQ Eiger BioPharmaceuticals, Inc. | $2.6M | 0.0× | Compare |
Notable Labs, Ltd. (NTBLQ) Latest News
29 Aug
Notable Labs, Ltd. to present data on Phase 2 volasertib program for AML at SOHO 2024. Presentation of Phase 2 program data and preclinical studies at SOHO 2024 could significantly impact Notable Labs' future clinical development and market positioning.
26 Aug
Thomas Bock, MD resigns as CEO of Notable Labs, Ltd.; Joseph Wagner, PhD appointed interim CEO. Company plans to initiate volasertib Phase 2 program soon. CEO transition and upcoming Phase 2 program initiation are significant events that could impact the company's future trajectory.
24 Jul
Notable Labs receives FDA clearance to proceed with Phase 2 study for volasertib in R/R AML. The FDA clearance and dosing plan agreement for Phase 2 study of volasertib in R/R AML is a significant development that could impact Notable Labs' future clinical outcomes and market performance.
9 May
Notable Labs CEO to participate in fireside chat at Citizens JMP Securities Life Sciences Conference 2024. Participation in conference may influence market sentiment and competitive positioning.
12 Apr
Notable Labs reports 2023 financial results and provides business update, focusing on clinical validation dataset, successful PPMP clinical data, and upcoming Phase 2 trial for volasertib in r/r AML patients. The article highlights significant developments in clinical validation, successful clinical data, and upcoming Phase 2 trial, which are expected to have a significant impact on Notable Labs' future and market performance.
9 Apr
Notable Labs presents design plan for PPMP-enabled Phase 2 trial with volasertib for relapsed/refractory AML at AACR 2024. The presentation of the Phase 2 trial design with potential companion diagnostic and dose optimization plan could significantly impact Notable Labs' future clinical development and market performance.
8 Apr
Notable Labs presented data on using cryopreserved samples in PPMP assay at AACR 2024, expanding platform potential. The data presented at AACR 2024 could significantly alter Notable Labs' trajectory and open new opportunities for partnerships and treatment options.
5 Mar
Notable Labs to present two posters at AACR 2024 on PPMP platform. The presentation of posters at AACR 2024 could significantly impact Notable Labs' future and market performance by showcasing advancements in their PPMP platform.
22 Feb
Notable Labs advances Volasertib Phase 2 program using Predictive Precision Medicine Platform, aiming to enroll clinically responding patients in Q2 2024. The utilization of PPMP to enrich the study population for clinical responders and reduce the risk, time, and cost of drug development could significantly impact Notable Labs' future and market performance.
18 Dec
Notable Labs and CicloMed report predictive precision medicine platform accurately predicted patient outcomes in fosciclopirox trial for leukemia. The successful prediction of patient outcomes in the trial could significantly impact Notable Labs' future drug development strategies and market performance.
13 Dec
Notable Labs donates $60,000 to MDS Foundation to accelerate progress for patients with Myelodysplastic Syndromes. The donation and collaboration with MDS Foundation may have a moderately noticeable influence on Notable Labs' future initiatives and market positioning.
11 Dec
Notable Labs donates $60,000 to MDS Foundation for cancer research and education. Donation may impact Notable Labs' reputation and research efforts.
4 Dec
Notable Labs CEO to participate in fireside chat at JMP Securities Hematology and Oncology Summit. Participation in summit may influence key areas like financial performance and competitive positioning.
14 Nov
Notable Labs, Ltd. filed Form 10-Q for third quarter 2023 with financial results of pre-Merger VBLT. The merger with VBL Therapeutics and financial results could moderately influence Notable Labs' future.
9 Nov
Notable Labs published data in JCO PO demonstrating PPMP potential for identifying drug combinations in JMML. The publication of data on PPMP's potential for identifying more effective pre-HSCT regimens for JMML patients could significantly impact Notable Labs' future and market performance.
16 Oct
Notable Labs completes merger with VBL Therapeutics, expects to trade on Nasdaq as NTBL, secures funding for operations until 2025, focuses on predictive precision medicines for cancer patients. The merger, funding, and focus on predictive precision medicines are expected to significantly impact Notable Labs' future trajectory and market performance.